Peter Cartwright
Peter Cartwright
businesses particular review short sold strategic whether
The more fundamental strategic review -- in particular as to whether any businesses get sold or not -- probably will happen, but not in the very short term.
appear generally growth held profits rate slower
The top-line growth rate was generally slower than expected, but that doesn't appear to have held profits back.
ball behind chain dragging
They are dragging a ball and chain behind them now.
commercial full research strategy update
Wednesday's the teaser, Thursday's the Full Monty. We should get a look at their R&D (research and development) strategy, pipeline, commercial strategy and an update on cost-cutting.
drift inexorable toward
There is an inexorable drift toward consolidation in the drug industry.
actions assumption clearly deal expect greater market pressure work
The pressure on SmithKline is clearly greater and, indeed, their actions have to show that. I expect the market will still work on the assumption that SmithKline will do a deal in the not-too-distant future.